According to the American Diabetes Association (ADA) 2022 guidelines, there is evidence supporting significant cardiovascular benefits of four FDA-approved GLP-1 RAs (liraglutide, albiglutide, semaglutide, and dulaglutide) and three FDA-approved SGLT2 inhibitors (empagliflozin, canagliflozin, and dapagliflozin), with lesser benefits seen with ertugliflozin, for patients with T2D and high risk of ASCVD (AD A, 2022). This evidence concerns the gene GLP1R and atherosclerosis.